What's happening
Writing a plain-English summary… Track this bill to get it by email.
Why it matters
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Headline styles
Sponsors
History
- Referred to consumer protection
- Referred to consumer protection
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Provides for the proper packaging and labeling of pharmaceutical drugs; creates penalties for intentional fraud
In Assembly Committee · Consumer Affairs And Protection · Sponsor Kevin Cahill
Full text
The text isn't available here yet. Check nysenate.gov.
Sponsor's memo
Title of bill
An act to amend the general business law, in relation to preserving the integrity and safety of pharmaceutical drugs
Purpose
To preserve the integrity and safety of pharmaceutical drugs; to protect consumers from false labeling and misrepresentations concerning pharmaceutical drugs.
Summary of provisions
This legislation would add section 392-j to article 26 of the general business law, related to false labels and misrepresentations concerning pharmaceutical drugs.
Legislative history
S.86 of 2007-08; S.6924 of 2005-06.
Justification
Trademark counterfeiting is a serious problem which is reportedly getting worse. The counterfeit goods trade comprises the sale of so-called knock-offs of brand-name products; pirated intellectual property; and, increasingly, falsely labeled pharmaceutical drugs.
It has been estimated that this illicit trade takes billions of dollars out of the state's economy, with an annual fiscal impact of over $2.6 billion in lost revenue. The counterfeit goods trade also has implications for public health and safety; this is particularly true where falsely labeled pharmaceuticals are involved.
The regulation of the pharmaceutical industry is primarily a federal matter; at the same time, the state has a significant role to play in protecting the health and safety of New York residents. In 2002, the federal Food and Drug Administration opened at least twenty (20) separate cases of illegal and fraudulent pharmaceutical drugs being distributed on the open market. This legislation would address the problem at the state level.
Fiscal implications
None.
Effective date
Immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.